AU1576501A - Methods to enhance and confine gene expression in cancer therapy - Google Patents

Methods to enhance and confine gene expression in cancer therapy

Info

Publication number
AU1576501A
AU1576501A AU15765/01A AU1576501A AU1576501A AU 1576501 A AU1576501 A AU 1576501A AU 15765/01 A AU15765/01 A AU 15765/01A AU 1576501 A AU1576501 A AU 1576501A AU 1576501 A AU1576501 A AU 1576501A
Authority
AU
Australia
Prior art keywords
confine
enhance
methods
gene expression
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15765/01A
Inventor
Yuen Kai Fung
Anne T'ang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of AU1576501A publication Critical patent/AU1576501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU15765/01A 1999-10-28 2000-10-27 Methods to enhance and confine gene expression in cancer therapy Abandoned AU1576501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16208599P 1999-10-28 1999-10-28
US60162085 1999-10-28
PCT/US2000/029783 WO2001030799A1 (en) 1999-10-28 2000-10-27 Methods to enhance and confine gene expression in cancer therapy

Publications (1)

Publication Number Publication Date
AU1576501A true AU1576501A (en) 2001-05-08

Family

ID=22584111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15765/01A Abandoned AU1576501A (en) 1999-10-28 2000-10-27 Methods to enhance and confine gene expression in cancer therapy

Country Status (2)

Country Link
AU (1) AU1576501A (en)
WO (1) WO2001030799A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125839A1 (en) * 2001-05-25 2002-12-19 Stefan Kubicka Regulating gene expression and viral replication by switching off an active mutated promoter of a repressor allows selective expression of therapeutic genes and viral vectors in tumor cells
US20030082722A1 (en) * 2001-08-08 2003-05-01 Bingliang Fang Method for amplifying expression from a cell specific promoter
GB0206357D0 (en) * 2002-03-18 2002-05-01 Univ Bath Cells
EP1625220A2 (en) * 2003-05-01 2006-02-15 MUSC Foundation For Research Development An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN103667345B (en) * 2013-12-02 2015-10-28 东南大学 A kind of Antioncogene magnetic composite nano particle and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) * 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
EP0870044B1 (en) * 1995-12-01 2004-04-14 Crucell Holland B.V. Regulated protein expression in stably transfected mammalian cells
US5989910A (en) * 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells

Also Published As

Publication number Publication date
WO2001030799A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
AU3316600A (en) Gene expression in bladder tumors
AU2001288432A1 (en) Materials and methods to potentiate cancer treatment
AU4972900A (en) Use of anti-vegf antibody to enhance radiation in cancer therapy
AU5481000A (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU5132800A (en) Expression of ets-domain proteins in cancer
AU1922301A (en) Differential gene expression in cancer
AU715620C (en) Therapeutic methods and uses
HUP9901908A3 (en) P16 expression constructs and their application in cancer therapy
AU2001245987A1 (en) Compositions and methods for gene therapy
AU1453301A (en) Methods of reversing drug resistance in cancer cells
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
EP0666313A3 (en) Targeting of telomerase in cancer gene therapy.
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001276462A1 (en) Use of natural products in cancer treatment
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AU4135600A (en) Prostate cancer associated human fibronectin gene and biallelic markers
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU5416700A (en) Differentially expressed genes in prostate cancer
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU4459100A (en) Cell cycle genes and methods of use
AU3349997A (en) Reg gene expression in cancer tissue
AU6149600A (en) Novel vector complexes and their use in gene therapy
AU7967901A (en) Tumour-cell specific gene expression and its use in cancer therapy
AU4462600A (en) Novel prostate-restricted gene expressed in prostate cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase